Hiponatreminin Tedavisinde Yeni Bir İlaç: Sglt-2 İnhibitörü

Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72(24):3200-3223. doi:10.1016/j.jacc.2018.09.020

Li J, Albajrami O, Zhuo M, Hawley CE, Paik JM. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15(11):1678-1688. doi:10.2215/CJN.02690320

Hsia DS, Grove O, Cefalu WT. An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-79. doi:10.1097/MED.0000000000000311.An

Shao SC, Chang KC, Lin SJ, et al. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: Head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. Cardiovasc Diabetol. 2020;19(1):1-11. doi:10.1186/s12933-020-0990-2

Ortiz-Flores AE, Araujo-Castro M, Pascual-Corrales E, Escobar-Morreale HF. Syndrome of inappropriate antidiuretic hormone secretion. Med. 2020;13(18):1000-1006. doi:10.1016/j.med.2020.10.002

Verbalis JG, Greenberg A, Burst V, et al. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion. Am J Med. 2016;129(5):537.e9-537.e23. doi:10.1016/j.amjmed.2015.11.005

Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: Compilation of the guidelines. J Am Soc Nephrol. 2017;28(5):1340-1349. doi:10.1681/ASN.2016101139

Lee MY, Kang HJ, Park SY, Kim HL, Han E, Lee EK. Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia. Clin Ther. 2014;36(9):1183-1194. doi:10.1016/j.clinthera.2014.07.010

Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9

Refardt J, Imber C, Sailer CO, et al. A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis. J Am Soc Nephrol. 2020;31(3):615-624. doi:10.1681/ASN.2019090944

Chen L, Larocque L, Efe O, Wang J, Sands JM, Klein JD. Balance in Diabetic Rats. 2017;352(5):517-523. doi:10.1016/j.amjms.2016.08.015.Effect